Cargando…
Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer
OBJECTIVE: To investigate the decisive role of preoperative serum thrombopoietin levels in the discrimination of benign and malignant ovarian pathologies and its value in the evaluation of treatment response. METHODS: Fifty patients with diagnoses of adnexal masses (25 benign, 25 malignant) were inc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Gynecologic Oncology and Colposcopy
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325354/ https://www.ncbi.nlm.nih.gov/pubmed/22523623 http://dx.doi.org/10.3802/jgo.2012.23.2.86 |
_version_ | 1782229427997900800 |
---|---|
author | Mermer, Timucin Terek, Mustafa Cosan Zeybek, Burak Ergenoglu, Ahmet Mete Yeniel, Ahmet Ozgur Ozsaran, Aydın Zekioglu, Osman |
author_facet | Mermer, Timucin Terek, Mustafa Cosan Zeybek, Burak Ergenoglu, Ahmet Mete Yeniel, Ahmet Ozgur Ozsaran, Aydın Zekioglu, Osman |
author_sort | Mermer, Timucin |
collection | PubMed |
description | OBJECTIVE: To investigate the decisive role of preoperative serum thrombopoietin levels in the discrimination of benign and malignant ovarian pathologies and its value in the evaluation of treatment response. METHODS: Fifty patients with diagnoses of adnexal masses (25 benign, 25 malignant) were included in the study. Blood samples were collected from all cases preoperatively. Age, menopausal status, adnexal mass size, preoperative CA-125 level, platelet count, the stage of the disease (FIGO stage), tumor grade, histologic subgroup, the residual tumor mass, ascites cytology, surgical procedures, and postoperative treatments were recorded for the malignant group. Response to treatment was evaluated based on the revised RECIST guideline. RESULTS: The preoperative serum thrombopoietin levels of the malignant cases (median, 98; range, 7 to 768) were significantly higher when compared with those of benign cases (median, 27; range, 13 to 131; p=0.004). The positive predictive value of CA-125 was found to be 79%, when it was used as a single marker; however it had risen to 85% when both CA-125 and thrombopoietin levels were used. There was no significant relationship between preoperative serum thrombopoietin levels and tumor grade, ascites cytology, presence of residual mass, and response to treatment. The preoperative serum thrombopoietin levels were significantly higher in stage III-IV cases and cases with serous histology. The post-treatment serum thrombopoietin levels in the malignant group were significantly lower as compared with the preoperative thrombopoietin levels. CONCLUSION: Thrombopoietin can play an additive role for prediction of ovarian cancer. |
format | Online Article Text |
id | pubmed-3325354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Korean Society of Gynecologic Oncology and Colposcopy |
record_format | MEDLINE/PubMed |
spelling | pubmed-33253542012-04-20 Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer Mermer, Timucin Terek, Mustafa Cosan Zeybek, Burak Ergenoglu, Ahmet Mete Yeniel, Ahmet Ozgur Ozsaran, Aydın Zekioglu, Osman J Gynecol Oncol Original Article OBJECTIVE: To investigate the decisive role of preoperative serum thrombopoietin levels in the discrimination of benign and malignant ovarian pathologies and its value in the evaluation of treatment response. METHODS: Fifty patients with diagnoses of adnexal masses (25 benign, 25 malignant) were included in the study. Blood samples were collected from all cases preoperatively. Age, menopausal status, adnexal mass size, preoperative CA-125 level, platelet count, the stage of the disease (FIGO stage), tumor grade, histologic subgroup, the residual tumor mass, ascites cytology, surgical procedures, and postoperative treatments were recorded for the malignant group. Response to treatment was evaluated based on the revised RECIST guideline. RESULTS: The preoperative serum thrombopoietin levels of the malignant cases (median, 98; range, 7 to 768) were significantly higher when compared with those of benign cases (median, 27; range, 13 to 131; p=0.004). The positive predictive value of CA-125 was found to be 79%, when it was used as a single marker; however it had risen to 85% when both CA-125 and thrombopoietin levels were used. There was no significant relationship between preoperative serum thrombopoietin levels and tumor grade, ascites cytology, presence of residual mass, and response to treatment. The preoperative serum thrombopoietin levels were significantly higher in stage III-IV cases and cases with serous histology. The post-treatment serum thrombopoietin levels in the malignant group were significantly lower as compared with the preoperative thrombopoietin levels. CONCLUSION: Thrombopoietin can play an additive role for prediction of ovarian cancer. Korean Society of Gynecologic Oncology and Colposcopy 2012-04 2012-04-03 /pmc/articles/PMC3325354/ /pubmed/22523623 http://dx.doi.org/10.3802/jgo.2012.23.2.86 Text en Copyright © 2012. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mermer, Timucin Terek, Mustafa Cosan Zeybek, Burak Ergenoglu, Ahmet Mete Yeniel, Ahmet Ozgur Ozsaran, Aydın Zekioglu, Osman Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title | Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title_full | Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title_fullStr | Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title_full_unstemmed | Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title_short | Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
title_sort | thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325354/ https://www.ncbi.nlm.nih.gov/pubmed/22523623 http://dx.doi.org/10.3802/jgo.2012.23.2.86 |
work_keys_str_mv | AT mermertimucin thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT terekmustafacosan thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT zeybekburak thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT ergenogluahmetmete thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT yenielahmetozgur thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT ozsaranaydın thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer AT zekiogluosman thrombopoietinanovelcandidatetumormarkerforthediagnosisofovariancancer |